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Background: Locally advanced and/or inflammatory breast cancer (LABC) is a heterogeneous disease.
Molecular markers may help to understand this heterogeneity. This paper reports the results of a study
assessing the potential prognostic or predictive value of HER-2, p53, cyclinD1, MIB1, ER and PgR expression
by immunohistochemistry from patients included in an EORTC–NCIC–SAKK trial.
Patients and methods: A total of 448 patients with a cytological or histological diagnosis of LABC were
randomised into a trial comparing two anthracycline-based neoadjuvant regimens. Chemotherapy was
followed by standard locoregional therapy. Survival was comparable in both arms. We collected and analysed
centrally paraffin-embedded tumour specimens from 187 (72.5%) of 258 patients that had a histological
diagnosis.
Results: Of the patients included in this molecular marker study 114 relapsed and 91 died. In the multivariate
analysis p53 positivity was associated with a shorter progression-free survival [hazard ratio (HR) = 1.96;
95% CI 1.33–2.91; P = 0.0008) and a shorter overall survival (HR = 1.98; 95% CI 1.28–3.06; P = 0.002). PgR
positivity predicted for a longer overall survival (HR = 0.54; 95% CI 0.35–0.83; P = 0.0045).
Conclusions: p53 was an independent factor predicting for survival. In order to clarify whether p53 is a pure
prognostic and/or a predictive factor, a phase III trial is being conducted (EORTC 10994/BIG 00-01 study)
using functional assay in yeast from frozen tumour samples.
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Introduction
Molecular predictive factors of response or resistance to chemo-
therapy in breast cancer are lacking in clinical practice. The list of
candidates is long and MDR1/gp170, topoisomerase II, S-phase,
HER-2, p53 and others have been analysed in many breast cancer
trials. Within this list two markers, namely HER-2 and p53,
seem very promising. Preclinical data regarding the relationship
between HER-2 and response to chemotherapy are contradictory
[1]. In the clinic the role of HER-2 as a predictive factor of
response to chemotherapy, specifically to anthracyclines, has
been suggested by several retrospective analyses conducted in
the context of prospective trials. Taken together these data sug-
gest that HER-2 is associated with sensitivity to doxorubicin [2].
TP53 is a key regulatory gene in the apoptotic pathway and
preclinical and clinical studies have shown that anticancer agents
achieve their cytotoxic effect through apoptosis. In vitro and
in vivo studies indicate that tumours containing wild-type p53
respond better to anthracyclines than p53-mutant tumours [3, 4].
One clinical study [5], recently updated [6], where TP53 gene
was analysed suggested that specific mutations may confer resist-
ance to anthracyclines.
The results of a large intergroup (EORTC–NCIC–SAKK)
phase III trial conducted on 448 patients presenting with locally
advanced and/or inflammatory breast cancers were recently
reported [7]. Patients were randomised between two different neo-
adjuvant anthracycline chemotherapy regimens. After six cycles
of chemotherapy, locoregional treatment was planned, followed
by tamoxifen for 5 years. After a median follow-up of 5.5 years,
no significant difference in terms of progression-free survival
(PFS) or overall survival (OS) was found between the two
chemotherapy arms. Patients with inflammatory breast cancer
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had a shorter median PFS than patients with locally advanced
breast cancer (24 months and 44 months, respectively). However,
both subgroups were heterogeneous, some patients having pro-
gressed very early and others remaining without progression
several years after diagnosis. Beyond the clinical presentation
(locally advanced versus inflammatory breast cancer) we attempted
to understand this heterogeneity with the help of molecular mark-
ers. Therefore, we collected tumour specimens from patients
included in the EORTC–NCIC–SAKK study and performed a
central immunohistochemical analysis of the following markers:
estrogen receptor (ER) and progesterone receptor (PgR), MIB-1,
HER-2, p53 and cyclin D1. This paper reports the results of a
retrospective assessment of the potential prognostic or predictive
value of these markers in relation to clinical response, PFS and
OS. By definition “prognostic factors are associated with either
the metastatic and/or growth rate potential of the primary tumour
and predictive factors are associated with relative sensitivity and/
or resistance to specific therapeutic agents” [8]. Some factors can
be both prognostic and predictive. We will elaborate on this in the
discussion.
Patients and methods
Patients and treatment
From May 1993 to April 1996, patients with locally advanced or inflamma-
tory breast cancer were included in a large EORTC–NCIC–SAKK random-
ised study that compared two neoadjuvant anthracycline-based regimens,
with dose-intensity in one regimen being twice that of the other. The eligi-
bility criteria for this trial are described by Therasse et al. [7]. Patients were
randomised to receive six cycles of neoadjuvant chemotherapy, either fluoro-
uracil 500 mg/m2 days 1 and 8 intravenously (i.v.), epirubicin 60 mg/m2 days
1 and 8 i.v., cyclophosphamide 75 mg/m2/day from day 1 to day 14 orally,
q 4 weeks (FEC 120), or epirubicin 120 mg/m2 day 1, cyclophosphamide
830 mg/m2 i.v. and granulocyte colony-stimulating factor (G-CSF) (Fil-
grastim) 5 µg/kg/day from day 1 to day 13 subcutaneously (EC regimen),
every 2 weeks. Tumour assessment was planned after three and six cycles of
chemotherapy in both arms. Locoregional treatment was planned after
chemotherapy and was flexible according to each centre’s policy. Tamoxifen
was started 4 weeks following day 1 of the last cycle of chemotherapy in all
patients irrespective of hormone-receptor status and was planned for a total of
5 years. All patients were followed in a standardised fashion after treatment
completion to determine the PFS and OS.
Central pathology review
Formalin-fixed or Bouin Hollande-fixed, paraffin-embedded tumour samples
from the primary tumour were obtained prior to the initiation of neoadjuvant
chemotherapy from participating EORTC institutions. Tumours were pro-
vided as unstained 5-µm tissue sections or as tumour blocks, in which case the
slides were prepared centrally. The tumours were graded on haematoxylin
and eosin (H&E) slides according to the Elston modified scoring scheme of
Bloom and Richardson [9] by a reference pathologist (S.D.B.) blinded to the
clinical outcome of the patient.
Immunohistochemical analysis
All immunohistochemical analyses were performed in a single reference
laboratory, using the unstained 5-µm tissue sections. The general protocol for
immunohistochemical staining was performed according to a standardised
method previously described by Clahsen et al. [10]. This standardised method
has been used in several retrospective studies on tissue sections from patients
treated within EORTC trials.
Except for HER-2, an antigen retrieval procedure was applied: tissue sec-
tions were pre-incubated in 10 mM sodium citrate solution and incubated
three times for 5 min in a 600 W microwave oven. Slides were then pre-
incubated for 15 min in phosphate-buffered saline (PBS) with 5% bovine
serum albumin (BSA) and incubated for 1 h at room temperature with the
following primary antibodies: mouse monoclonal HER-2 Abs CB11 (Bio-
genex, undiluted), mouse monoclonal p53 Abs DO-7 (Dako, 1/100 dilution),
mouse monoclonal Cyclin D1 Abs DCS-6 (Novocastra, 1/40 dilution), mouse
monoclonal estrogen receptors Abs 1D5 (Dako, 1/100 dilution), mouse mono-
clonal progesterone receptors Abs PGR-1A6 (Biogenex, 1/20 dilution),
mouse monoclonal Ki-67 antigen Abs MIB-1 (Immunotech, 1/20 dilution).
Sections were washed with PBS and reacted with streptavidin–biotin per-
oxidase reagents (Dako) and diaminobenzidine chromogen. Sections were
finally counterstained with haematoxylin (5 min).
In all series and for each antibody, positive controls (known cases of breast
carcinoma) and negative controls (primary antibody omitted) were included.
All slides were scored independently by two investigators (S.D.B. and
H.B.) without patient information. The method of counting and scoring the
immunostaining and the definition of a cut-off value were established for
each antibody according to previous studies before starting the analyses; all
details are described below. All discrepancies in scoring between the two
investigators were resolved by consensus.
p53 overexpression. Scoring was done using a semiquantitative system
according to a method previously described [10]. Mean nuclear staining
intensity (MSI) was evaluated and could vary from 0 (none), 1 (weak),
2 (moderate) to 3 (strong). Percentage of positive tumour cell nuclei (PPN)
was estimated and values were given: 0 (0%), 1 (1–25%), 2 (26–50%),
3 (51–75%) and 4 (>75%). The addition of these two values (MSI and PPN)
results in the p53 staining score (range 2–7). Expression of p53 was con-
sidered as positive for scores ≥4 [10].
HER-2 overexpression. As previously described, a tumour was considered as
positive if a clear circonferential membranous positivity was found in the
tumour cells either focally or throughout the tumour, as defined in previous
studies [11]. Tumour cells which showed a granular cytoplasmic staining
were considered to have normal HER-2 expression. The proportion of HER-2
positive cells was determined semi-quantitatively as the percentage of inva-
sive tumour cells ranging from 0% to 100% from the entire tissue section.
MIB-1 positivity. Only clear nuclear staining in tumour cells was considered
positive. The percentage of positively stained cells was calculated from the
number of brown nuclei seen in a sample of 200 tumour cells [12]. We
selected the threshold of 20% (<20%, negative; ≥20%, positive), as used in a
previous EORTC immunohistochemical study [10].
ER and PgR status. Only clear nuclear staining in tumour cells was con-
sidered positive. The proportion of ER and PgR-positive cells was deter-
mined as the percentage of invasive tumour cells ranging from 0% to 100%
from the entire tissue section. The threshold of 10% positivity was chosen
as the cut-off value, according to a current consensus recommendation [13].
The staining intensity was scored from 0 to 3, in a similar fashion as for p53
(see above).
Cyclin D1 expression. Only clear nuclear staining in tumour cells was con-
sidered positive. Rarely, a weak cytoplasmic staining was observed; this was
considered to be non-specific. The percentage of positive cells and the stain-
ing intensity were determined as described above. We chose a cut-off value of
10% (<10%, negative tumours; ≥10%, positive tumours), as used in previous
studies [14].
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Statistical methods
Life tables were constructed to examine PFS and OS, using the Kaplan–Meier
method [15] and were compared using the log-rank test [16]. A proportional
hazards regression model [17] with stratification for treatment [18] was used
in the univariate and multivariate analysis. A step-down (backward) variable
selection procedure was used to fit the multivariate model [19]. A two-sided
test was used at the 5% level of significance.
In the statistical analysis of prognostic value, we planned to analyse
molecular marker expression by immunohistochemistry both as continuous
and dichotomous variables. For each marker the definitions of positivity and
negativity were selected before we performed the analysis based on previous
studies, as described in the previous section. The correlation between the
response status and the predictive value of each biological factor has been
analysed in a univariate and multivariate logistic regression model [17, 19].
All analyses testing prognostic significance of the different factors identified
have been performed with SAS software. The survival data and response
status were provided directly from Software for the Management and Ana-
lysis of Randomised Trials (SMART). The correlation between the response
status and the predictive value of each biological factor has been analysed in a
univariate analysis.
Results
Patient and tumour characteristics
From May 1993 to April 1996 448 patients were included in the
EORTC–NCIC–SAKK trial. Eleven patients were not eligible.
One of the inclusion criteria for this protocol was a cytological or
histological diagnosis of breast carcinoma. We were able to col-
lect tumour specimens from 187 (72.5%) of 258 patients that had
a histological diagnosis. Eight cases were not evaluable for the
immunohistochemical analysis (no invasive carcinoma detected
in six cases; technically unsuitable specimen in two cases). Con-
sequently tumour specimens from 179 patients were included in
the immunohistochemical study, leaving 258 patients who were
treated in the clinical trial but not entered in this translational
research study (no tumour specimen collected). Characteristics
of patients in these two groups were well balanced for age,
tumour presentation (locally advanced versus inflammatory),
menopausal status, chemotherapy regimen allocated and clinical
response to chemotherapy (Table 1). Tumour characteristics
(histological grade and molecular markers) of the 179 patients
included in this study are listed in Table 2.
Table 1. Comparison of patient characteristics included in the European 
Organisation for Research and Treatment of Cancer (EORTC) 10921 study: 
group A, patients included in the prognostic factor study (PF study) and 
group B, patients not included in the PF study
aNo survival differences between the two treatment arms (FEC versus       
EC + G-CSF).
CR, complete response; EC, epirubicin, cyclophosphamide and granulocyte 
colony-stimulating factor (G-CSF) (Filgrastim); FEC, 5-fluorouracil, 
epirubicin, cyclophosphamide; PR, partial response; NC, no change; PD, 
progressive disease.
Characteristics Group A Group B
n (%) n (%)
No. of patients (n) 179 258
Age (years)
Median 49 49
Range 27–75 26–74
WHO performance status
0 163 (91) 223 (86)
1 16 (9) 35 (14)
Tumour
Locally advanced cancer (any T, N2,3, M0 
or T4a,b,c, any N, M0)
103 (58) 131 (51)
Inflammatory cancer (T4d, any N, M0) 76 (42) 127 (49)
Menopausal status
Pre 89 (50) 130 (50)
Post 88 (49) 121 (47)
Unknown 2 (1) 7 (3)
Clinical response to chemotherapy
CR 48 (27) 75 (29)
PR/NC/PD 131 (73) 183 (71)
Treatmenta
FEC 88(49) 129(50)
EC + G-CSF 91(51) 129(50)
Table 2. Tumour characteristics: histological grade and 
molecular markers
ER, estrogen receptor; PF, prognostic factor; PgR, 
progesterone receptor.
Tumour characteristics PF study (n = 179)
n (%)
Histological grade
Grade I and II 82 (58)
Grade III 60 (42)
ER
Negative <10% 102 (57)
Positive ≥10% 77 (43)
PgR
Negative <10% 60 (34)
Positive ≥10% 117 (66)
MIB-1
Negative <20% 42 (25)
Positive ≥20% 128 (75)
HER-2
Negative 132 (74)
Positive 47 (26)
p53 overexpression
Negative (score <4) 126 (70)
Positive (score ≥4) 53 (30)
Cyclin D1
Negative <10% 126 (71)
Positive ≥10% 52 (29)
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Survival
Of the 179 patients included in this molecular markers study
114 relapsed and 91 died.
Univariate analysis for PFS and OS
A first univariate analysis was performed on the following
parameters analysed as dichotomous variables: tumour grade
(I/II versus III), ER status [percentage of cells stained (%CS)
<10 versus ≥10], PgR status (%CS <10 versus ≥10), MIB-1 per-
centage (%CS <20 versus ≥20), HER-2 overexpression (%CS = 0
versus >0), p53 overexpression (score <4 versus ≥4) and cyclin
D1 overexpression (% CS <10 versus ≥10). This analysis demon-
strated that two factors were significantly associated with a
shorter PFS and OS: ER negativity and p53 positivity (Table 3).
PgR negativity was associated with a shorter PFS and OS; this
difference was statistically significant for OS (P = 0.007), but not
for PFS (P = 0.23). Progression-free survival and OS curves
according to immunohistochemically defined p53 status are shown
in Figures 1 and 2.
A second univariate analysis was performed on immuno-
histochemical parameters which were analysed as continuous
variables. Again ER negativity and p53 overexpression were
significantly associated with a worse outcome in terms of PFS
and OS (Table 4). Progesterone receptor negativity and MIB-1
positivity were associated with a shorter PFS and OS; with both
markers this difference was statistically significant for OS
(P = 0.002 and 0.004, respectively), but not for PFS (P = 0.22 and
0.09, respectively).
Multivariate analysis for PFS and OS
Characteristics were analysed as dichotomous variables in the first
multivariate analysis and as continuous variables in the second.
All the factors found to be significant at the 0.1 level in the uni-
variate analysis were included in the multivariate Cox regression
model for their relation to PFS and OS. Consequently, grade and
HER-2 were not analysed in the first multivariate analysis, and
HER-2 and cyclin D1 were not analysed in the second multi-
variate analysis.
In both analyses, p53 positivity (tumour with a score ≥4 or with
a high percentage of positive cells) was found to be an independ-
ent prognostic factor associated with a statistically significant
higher risk of progression and death (Tables 5 and 6).
In both multivariate analyses, PgR negativity was found to be
an independent prognostic factor associated with a statistically
significant higher risk of death (Tables 5 and 6).
Table 3. Univariate analysis of grade and molecular markers predicting for progression-free survival (PFS) and overall survival (OS) 
(characteristics analysed as dichotomous variables)
O/N, observations (events)/number of patients (total); HR, hazard ratio; NR, not reached; CI, confidence interval; %CS, percentage of cells stained.
Variable Progression-free survival Overall survival
O/N Median (months) HR 95% CI P O/N Median (months) HR 95% CI P
Grade
I/II 52/82 33 0.97 0.64–1.48 0.89 38/82 79 1.2 0.74–1.91 0.47
versus III 37/60 38 31/60 58
ER
Negative (%CS <10) 70/102 19 0.6 0.41–0.88 0.008 61/102 39 0.45 0.29–0.7 0.0004
Positive (%CS ≥10) 44/77 54 30/77 NR
PgR
Negative (%CS <10) 39/60 19 0.79 0.53–1.15 0.23 37/60 37 0.56 0.37–0.85 0.007
Positive (%CS ≥10) 73/117 39 52/117 79
MiB-1
Negative (%CS <20) 25/42 46 1.22 0.78–1.91 0.38 17/42 79 1.67 0.98–2.85 0.06
Positive (%CS ≥20) 84/128 26 68/128 56
HER-2
Negative (%CS = 0) 83/132 34 1.12 0.74–1.70 0.58 68/132 58 0.91 0.57–1.47 0.71
Positive (%CS >0) 31/47 25 23/47 NR
p53
Negative (score <4) 70/126 47 2.16 1.48–3.16 <0.0001 57/126 79 1.95 1.27–2.98 0.002
Positive (score ≥4) 44/53 16 34/53 33
Cyclin D1
Negative (%CS <10) 84/126 24 0.70 0.46–1.07 0.1 68/126 50 0.65 0.40–1.04 0.07
Positive (%CS ≥10) 30/52 53 23/52 79
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Predictive factors of a clinical complete response to 
chemotherapy
A complete clinical response to neoadjuvant chemotherapy was
observed in 48 of 179 patients (27%). In the univariate analysis,
cyclin D1-negative tumours were associated with a lower rate of
complete clinical response (P = 0.051) (Table 7). No statistically
significant correlation between grade or immunohistochemical
status of ER, PgR, MIB-1, HER-2 or p53 and a clinical complete
response to chemotherapy was found (Table 7).
Discussion
In the literature few studies report on biological factors in locally-
advanced/inflammatory breast cancer [5, 20, 21]. This is the
largest biological markers study conducted so far in this setting.
In early breast cancer ER and PgR status are weak prognostic
factors [22] and well established predictive factors of response to
tamoxifen and other hormonal manipulations [23]. In locally
advanced and/or inflammatory breast cancers the prognostic or
predictive value of hormone receptors remains controversial
[21, 24]. In our study, PgR status was found to be an independent
factor predicting for OS (Tables 5 and 6). In the multivariate
analysis for OS, ER status lost its significance (Tables 5 and 6).
This is most probably because of its close correlation with PgR
(in the multivariate analysis for OS, ER was removed from the
model in favour of PgR). The fact that PgR is an independent
factor for OS, but not for PFS seems paradoxical. We hypo-
thesised that we missed its prognostic information for PFS due to
the relatively small number of patients analysed.
In our series HER-2 did not predict for either PFS or OS in
the univariate analysis. The potential pure prognostic value of
HER-2 remains controversial, as shown in a recent meta-analysis
[25]. Regarding its predictive value, data in the literature suggest
that HER-2 overexpression is associated with anthracycline
sensitivity and that this sensitivity increases with dose escalation
[2]. In our study patients received chemotherapy regimens with a
high dose of anthracyclines in both treatment arms. Therefore,
our study design is not optimal to evaluate the hypothesis of an
association between HER-2 overexpression and anthracycline
sensitivity. Similarly, there are data in the literature that suggest
Figure 1. Progression-free survival of patients according to p53 status 
defined by immunohistochemistry. The numbers below the years on the x 
axis refer to patients at risk.
Table 4. Univariate analysis of molecular markers predicting for progression-free survival and overall survival 
(characteristics analysed as continuous variables)
aHazard ratio (HR) represents the increase of the relative risk when the percentage of cells stained (%CS) rises 
from x% to x+25%.
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PgR, progesterone receptor.
Variable Progression-free survival Overall survival
HRa 95% CI P HRa 95% CI P
ER (%CS) 0.83 0.72–0.97 0.015 0.74 0.62–0.88 <0.001
PgR (%CS) 0.92 0.81–1.05 0.22 0.79 0.68–0.92 0.002
MIB-1 (%CS) 1.23 0.97–1.56 0.09 1.45 1.13–1.88 0.004
HER-2 (%CS) 1.03 0.92–1.16 0.61 0.99 0.86–1.12 0.82
p53 (%CS) 1.30 1.17–1.46 <0.0001 1.3 1.15–1.48 <0.0001
Cyclin D1 (%CS) 0.92 0.7–1.19 0.51 0.94 0.7–1.26 0.68
Figure 2. Overall survival of patients according to p53 status defined by 
immunohistochemistry.
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that HER-2-positive tumours may be less sensitive to tamoxifen
than HER-2-negative tumours [2]. In our study all patients
received tamoxifen and the results do not suggest an inverse
association between HER-2 overexpression and tamoxifen
sensitivity.
In this study p53 was a strong independent factor predicting for
PFS and OS. We first performed a multivariate analysis with
molecular markers as dichotomous variables using a predefined
score detailed in the methods section. In this multivariate analysis
p53 was the only factor associated with an increased risk of pro-
gression (HR = 1.96) and the strongest factor associated with an
increased risk of death (HR = 1.98) (Table 5). We then performed
a second multivariate analysis, the factors being analysed as
continuous variables. Again p53 emerged as the only factor pre-
dicting for a shorter PFS and the strongest factor predicting for a
shorter OS (Table 6).
The risk of false positive and false negative results is higher
when p53 is assessed by the immunohistochemical method as
compared with molecular biology methods (e.g. denaturating
gradient gel electrophoresis, genomic p53 sequencing method)
[6, 26]. With immunohistochemistry there is a risk of false
negative cases related to the type of p53 mutation. With many p53
gene mutations, p53 protein half-life is increased and immuno-
histochemistry detects the protein in the nucleus, but when p53
gene mutations encode unstable proteins (nonsense mutations,
splicing mutations) immunohistochemistry remains negative
(‘null mutations’). These mutations have been found to account
for 25–47% of all p53 mutations in series of patients with early
breast cancers [27, 28]. These specific mutations were probably
uncommon in our series and this may explain our observation:
p53 by immunohistochemistry was a strong independent
prognostic factor in this subset of high risk tumours. We could
hypothesise that the use of a more sensitive method (e.g. denatur-
ating gradient gel electrophoresis, genomic p53 sequencing
method) could only have increased the independent prognostic
value of p53 assessed by immunohistochemistry.
In our series we did not find a correlation between p53 status
and clinical response to chemotherapy (Table 7). Amongst other
possibilities two reasons may explain this observation. First the
number of events (number of clinical complete responses) was
small in our series and we may have missed a correlation by a
lack of statistical power. Secondly, as discussed previously,
immunohistochemistry is not the best method to assess p53. In
five trials conducted in the neoadjuvant setting where p53 status
was assessed by immunohistochemistry, no correlation was
found between p53 status and clinical response to chemotherapy
[6, 29–32]. While in one clinical study [5], recently updated [6],
where p53 was assessed by temporal temperature gradient gel
Table 5. Multivariate analysis of molecular markers predicting for progression-free survival and overall 
survival (characteristics analysed as dichotomous variables)
aIn the univariate analysis for progression-free survival, PgR and MIB-1 were not found to be significant at 
the 0.1 level, and therefore were not included in the multivariate analysis.
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; NS, not significant; PgR, progesterone 
receptor.
Variable Progression-free survival Overall survival
HR 95% CI P HR 95% CI P
ER NS (0.07) NS (0.16)
PgR –a 0.54 0.35–0.83 0.0045
MIB-1 –a NS (0.1)
p53 1.96 1.33–2.91 0.0008 1.98 1.28–3.06 0.002
Cyclin D1 NS (0.6) NS (0.48)
Table 6. Multivariate analysis of molecular markers predicting for progression-free survival and overall 
survival (characteristics analysed as continuous variables)
aHazard ratio (HR) represent the increase of the relative risk when the percentage of cells stained (%CS) rises 
from x% to x+25%.
bIn the univariate analysis for progression-free survival, PgR was not found to be significant at the 0.1 level, 
and therefore was not included in the multivariate analysis for PFS.
CI, confidence interval; ER, estrogen receptor; NS, not significant; PgR, progesterone receptor.
Variable Progression-free survival Overall survival
HRa 95% CI P HRa 95% CI P
ER (%CS)   NS (0.22)   NS (0.09)
PgR (%CS) –b 0.79 0.68–0.93 0.004
MIB-1 (%CS)   NS (0.57) NS (0.32)
p53 (%CS) 1.27 1.13–1.43 <0.0001 1.29 1.13–1.47 0.0001
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electrophoresis (TTGE) and genomic sequencing, specific p53
mutations were associated with resistance to anthracyclines.
Pathologically assessed complete response may be a better surro-
gate for chemotherapy efficacy than clinical response. Therefore
biological markers predicting for a pathological complete response
(pCR) would be of great value. However, in view of the small
number of patients who achieved a pCR, we decided not to
evaluate the possible correlation between p53 status (or other
markers) and pathological response.
Our results do not allow us to conclude whether p53 is a pure
prognostic, or a mixed prognostic and predictive factor. Pre-
clinical data suggest that p53-mutated tumours are less sensitive
to anthracyclines [3, 4], but remain sensitive to taxanes [33–35].
Moreover, the correlation between p53 status and pCR, that we
were unable to address, needs to be evaluated. In order to test this
hypothesis a large intergroup phase III clinical trial is being
conducted (EORTC, SAKK, Swedish and Angloceltic groups)
under the auspices of the Breast International Group (EORTC
10994/BIG 00-01 study). Patients with large operable or locally
advanced breast cancer are randomised to receive six cycles
of neoadjuvant chemotherapy, either an anthracycline-based
regimen or a docetaxel-based regimen, followed by locoregional
treatment and antihormonal treatment when indicated. In this
study, p53 status will be determined by using a functional assay
in yeast that detects functionally important p53 mutations [36].
This test gives direct information regarding p53 function (detects
biologically important mutations) and is theoretically more sensi-
tive than sequencing because it is insensitive to contamination of
samples with normal tissue. We will measure the correlation
between p53 assessment by immunohistochemistry method and
functional test as part of a side study. The functional test will be
performed from frozen tumour samples taken by double trucut
biopsy or by single incisional biopsy, as we have shown that the
material from both biopsies gives identical results [37]. These
frozen samples will also be assessed by cDNA microarray tech-
nology, with the hope of identifying a gene expression profile
that predicts ‘exquisite’ sensitivity to a taxane-based regimen.
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